Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808923 | 1.00 | CYP4F2 (0.40) | CYP4F2CYP4A11PTGS1NAMPTGPR132 | |
| SCHEMBL9105503 | 0.86 | PTGS1 (0.36) | CYP4F2CYP4A11PTGS1GPR132 | |
| SCHEMBL12473747 | 0.82 | ABL1 (0.34) | NAMPT | |
| SCHEMBL10065476 | 0.80 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL14856727 | 0.80 | CYP4F2 (0.33) | CYP4F2CYP4A11PTGS1 | |
| SCHEMBL185854 | 0.78 | KDM4E (0.45) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL2809256 | 0.78 | KDM4E (0.48) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL2805627 | 0.78 | KDM4E (0.45) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL2809274 | 0.78 | KDM4E (0.48) | CYP4F2CYP4A11GPR132 | |
| SCHEMBL186662 | 0.77 | VNN1 (0.40) | CYP4F2CYP4A11GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937073-B2 | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8901127-B2 | Pyridazin derivatives as antagonists of the bradykinin B1 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-02 | — | — | US | disclosed |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8372838-B2 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-12 | — | — | US | disclosed |
| US-20120208823-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142695-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | CYP4F2 2566/4885CYP4A11 828/4885PTGS1 182/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CYP4F2 874/4885CYP4A11 223/4885PTGS1 988/4885 |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HRH2 | CYP4F2 419/4885CYP4A11 643/4885PTGS1 128/4885 |
| US-20120208823-A1 | New Compounds | ABCG2, SDHA, UGT2B7 | CYP4F2 9/4885CYP4A11 222/4885PTGS1 2196/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CYP4F2 874/4885CYP4A11 223/4885PTGS1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.